Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ CD229 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA584036
Description
Immunogen sequence: KRKGRCSVPA FCSSQAEAPA DTPEPTAGHT LYSVLSQGYE KLDTPLRPAR QQPTPTSDSS SDSNLTTEED EDRPEVHKPI SGRYE.
CD229 (Ly9) is a cell surface receptor of the CD150 family, which includes also e.g. CD48 and CD224. Receptors of this family regulate cytokine production and cytotoxicity of lymphocytes and NK cells. High levels of CD229 are found on T and B cells, where its expression increases during their maturation. It is absent on granulocytes, bone marrow-derived dendritic cells, platelets and erythrocytes. CD229 has been also reported on mouse monocytes and NK cells. CD229 interacts homophilically through its N-terminal domain and localizes to the contact site between T cells and antigen presenting B cells during antigen-dependent immune synapse formation.
Specifications
CD229 | |
Polyclonal | |
Unconjugated | |
Ly9 | |
AI893573; CD229; CDABP0070; Cell surface molecule Ly-9; hly9; Lgp100; LY9; Ly-9; Lymphocyte antigen 9; mLY9; RP11-312J18.1; Signaling lymphocytic activation molecule 3; SLAM family member 3; SLAMF3; T100; T-lymphocyte surface antigen Ly-9 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
4063 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot | |
0.6 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
Q9HBG7 | |
Ly9 | |
Recombinant protein corresponding to Human LY9. Recombinant protein control fragment (Product #RP-101244). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction